Look through the key statistics analysis before diving in deeper into our report:
Parameter | Current result | Assessment |
---|---|---|
Meta title | HER2+ Breast Cancer Treatment | PERJETA® (pertuzumab) | As meta title is a ranking factor, it's quite important to stick to search engine recommended length of aroun 50-60 characters. This website's meta title is 53 characters long. |
Description | Learn about PERJETA®, a neoadjuvant and metastatic breast cancer treatment for patients with HER2-positive breast cancer. What does PERJETA treat? PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer. PERJETA® (pertuzumab) is approved for use prior to surgery in combination with Herceptin® (trastuzumab) and docetaxel in people with HER2-positive, locally advanced, inflammatory, or early stage (tumor is greater than 2 cm in diameter or node positive) breast cancer. PERJETA should be used as part of a complete treatment regimen for early stage breast cancer. This use of PERJETA is based on an improvement in the percentage of patients whose cancer shrinks or disappears after treatment. Currently, no data have shown whether or not treatment with PERJETA prior to surgery improves survival. • The safety of PERJETA in combination with doxorubicin-containing regimens has not been established • The safety of PERJETA administered for greater than 6 cycles for early-stage breast cancer has not been established. Important Safety Information • PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure) • Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects — If you think you may be pregnant, you should contact your healthcare provider immediately — If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report PERJETA exposure to Genentech at 1-888-835-2555 • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA • Other possible serious side effects of PERJETA therapy include: — Infusion-related reactions — Severe allergic reactions (hypersensitivity reactions/anaphylaxis) • PERJETA has only been shown to work in people with HER2-positive breast cancer • The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are: — Diarrhea — Hair loss — Low levels of white blood cells with or without a fever — Nausea — Feeling tired — Rash — Damage to the nerves (numbness, tingling, pain in hands/feet) • The most common side effects of PERJETA when given with Herceptin and docetaxel as part of an early breast cancer regimen before surgery are: — Hair loss — Diarrhea — Nausea — Low levels of white blood cells with or without a fever • The most common side effects of PERJETA when given with Herceptin and docetaxel following 3 cycles of epirubicin, cyclophosphamide, and fluorouracil as part of an early breast cancer regimen before surgery are: — Feeling tired — Hair loss — Diarrhea — Nausea — Vomiting — Low levels of white blood cells with or without a fever • The most common side effects of PERJETA when given with Herceptin, docetaxel, and carboplatin as part of an early breast cancer regimen before surgery are: — Feeling tired — Hair loss — Diarrhea — Nausea — Vomiting — Low levels of white blood cells with or without a fever — Low platelet count — Low levels of red blood cells You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information including most serious side effects. | This meta description is 4040 characters in length. Google suggests up to 320 characters at the very most to make sure the whole meta description is visible in search results page. |
<meta> keywords | PERJETA, Herceptin, PERJETA and Herceptin, metastatic breast cancer treatment, pertuzumab, her2-positive metastatic breast cancer, Genentech, mbc, her2+, neoadjuvant | Strangely enough, meta keywords still seem to be used. We would not go down that road unless very carefully - meta keywords have not been known as a positive ranking factor for a while now. |
Site speed | Around 3.267 seconds | Website ranking and usability can be greatly improved by reducing the time it takes to load it. |
Alexa global rank | 3577440, as last checked | Based on Alexa Global, we can assume the website is not very popular. Mind you, Alexa's worth is questionable at best. |
Quantcast | Current rank, according to our database, is at 83705 | The website seems to enjoy good popularity, according to Quantcast. |
Links on homepage | Around 47 links | This is a well-judged amount of links for a homepage. |
Backlinks amount | Approximately 26 | The number of backlinks seems awfully low. If possible, the webmaster should work towards building more through quality content and public awareness. |
HTML size | 63.7KB | Ah. Well. We were hoping for better results... We would urge the website owners to improve load speed as soon as possible. |
Website host server overview | Server status: online. Server IP address for this website is 13.56.110.92. | We apologize, but for some reason we were unable to gather enough data to provide a detailed insight at this time. |
If the basic information we presented you with above is not enough, get ready to dive in much deeper!
Now that the numbers are taken care of, we can go deeper and try to analyse the website from a user's perspective. More specifically, let's see if we can identify the target audience as well as a few related websites and categories.
Parameter | Current result | Assessment |
---|---|---|
Alternative websites | her2treatment.com herceptin.com kadcyla.com her2support.org cancerchemotherapyreviews.com |
These websites fall into the same categories as perjeta.com, more or less. By extension, they compete with the analysed website for the same target audience. |
Trying to acquire very accurate visitor data is immensely difficult and can only be done when given direct access to the server. However, there are ways to get approximate numbers.
The numbers themselves probably say enough, but we'll add some insight where possible.
Parameter | Current result | Assessment |
---|---|---|
Approximate time on site | 3:54 | Wow, that's a great average result! The website must have some incredible content to keep visitors occupied. |
ALEXA rating is based on the number of visitors a given page receives. The higher the visitor count, the higher the rating. Currently, ALEXA has over 4 million websites indexed. If you sense cynicism in our words, you're not mistaken - we think Alexa rating is overrated, to put it mildly. A website's worth (and contextual popularity) is more than the sum of the views. So take the rank with a grain of salt.
QUANTCAST is a data processing company that mostly gathers information for advertising companies. It specializes in real-time audience analysis and, as you may have gathered, is really quite similar to Alexa, if perhaps not as infamous. To our knowledge, the company has rated and ranked approximately 17558762 websites so far. There is always a caveat with these sort of ranking systems - they don't really take any context into account. As such, their usefulness is debatable at best. Don't overthink this rank - it's just a number, really.
Servers are physical storage devices that contain all the files and databases associated with a specific website, sometimes more than one. At times, a server makes up several virtual devices - separate servers used for shared hosting (tends to be cheaper). Entering website address into the address bar of your browser starts the request process during which your browser contacts the server and asks for specific files and database entries in order to display the requested website.
What follows is certainly very geeky, but informative for the knowing. Dig in:
Header detail |
---|
HTTP/1.1 200 OK Accept-Ranges: bytes Content-Type: text/html; charset=UTF-8 Date: Sun, 01 Oct 2017 22:40:15 GMT ETag: "fdbc-55a61ee74c9a2" Last-Modified: Sat, 30 Sep 2017 06:05:42 GMT Server: Apache ServerID: web01 Content-Length: 64956 Connection: keep-alive |
WHOIS |
---|
Domain Name: PERJETA.COM Registry Domain ID: 1653158048_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.safenames.net Registrar URL: http://www.safenames.net Updated Date: 2017-05-01T03:37:02Z Creation Date: 2011-04-27T15:53:02Z Registry Expiry Date: 2019-04-27T15:53:02Z Registrar: SafeNames Ltd Registrar IANA ID: 447 Registrar Abuse Contact Email: Registrar Abuse Contact Phone: Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: HLRNS1.ROCHE.COM Name Server: NS1.ROCHE.COM Name Server: NS2.ROCHE.COM DNSSEC: unsigned URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/ >>> Last update of whois database: 2017-09-05T11:05:14Z <<< For more information on Whois status codes, please visit https://icann.org/epp NOTICE: The expiration date displayed in this record is the date the registrar's sponsorship of the domain name registration in the registry is currently set to expire. This date does not necessarily reflect the expiration date of the domain name registrant's agreement with the sponsoring registrar. Users may consult the sponsoring registrar's Whois database to view the registrar's reported date of expiration for this registration. TERMS OF USE: You are not authorized to access or query our Whois database through the use of electronic processes that are high-volume and automated except as reasonably necessary to register domain names or modify existing registrations; the Data in VeriSign Global Registry Services' ("VeriSign") Whois database is provided by VeriSign for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. VeriSign does not guarantee its accuracy. By submitting a Whois query, you agree to abide by the following terms of use: You agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to VeriSign (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of VeriSign. You agree not to use electronic processes that are automated and high-volume to access or query the Whois database except as reasonably necessary to register domain names or modify existing registrations. VeriSign reserves the right to restrict your access to the Whois database in its sole discretion to ensure operational stability. VeriSign may restrict or terminate your access to the Whois database for failure to abide by these terms of use. VeriSign reserves the right to modify these terms at any time. The Registry database contains ONLY .COM, .NET, .EDU domains and Registrars. |
Now that you are hopefully done with perjeta.com, we invite you to read more of our in-depth reports. Try entering a new domain address in the search form at the top of this page, or on the homepage. Alternatively, refer to this list for more website overviews:
We have found so many alternative TLD extensions for perjeta.com. Here is the full list with 580 entries:
The following list of most frequent domain address mistypes associated with perjeta.com contains at least 1233 entries: